<DOC>
	<DOCNO>NCT01034592</DOCNO>
	<brief_summary>This single-center , single arm , open-label study oral lenalidomide monotherapy administer red blood cell ( RBC ) transfusion dependent adult subject Diamond-Blackfan Anemia ( DBA ) . Primary Objective : To evaluate erythroid response rate measure rate red blood cell transfusion independence ( MDS IWG 2000 Criteria apply ) Secondary Objective : 1 ) To evaluate tolerability safety profile lenalidomide patient DBA inherit marrow failure syndromes 2 ) To correlate response lenalidomide biologic surrogate DBA include ribosomal protein mutation status , ex vivo erythroid colony growth , microarray gene expression</brief_summary>
	<brief_title>Pilot Lenalidomide Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia</brief_title>
	<detailed_description>This pilot study utilize intra-patient dose escalation design . Cycles 28 day length . Subjects receive lenalidomide 2.5 mg weekly day 1-21 cycle 1 ( dose level 1 ) . If patient experience grade &gt; 3 hematologic non-hematologic toxicity , dose increase 2.5 mg twice weekly day 1-21 cycle 2 ( dose level 2 ) . If patient experience grade &gt; 3 hematologic non-hematologic toxicity , dose increase 5 mg twice weekly day 1-21 cycle 3 ( dose level 3 ) . If patient experience grade &gt; 3 hematologic non-hematologic toxicity , dose increase 5 mg thrice weekly day 1-21 cycle 4 ( dose level 4 ) . Patients experience grade &gt; 3 hematologic non-hematologic toxicity dose level 1 discontinue study . Patients experience grade &gt; 3 hematologic non-hematologic toxicity dose level 2 , 3 , 4 lenalidomide hold dose reduce accord protocol dose interruption/modification algorithm ( section 5.5.3 ) . If least minor erythroid response achieve end 8 cycle treatment , patient discontinue study . If minor major erythroid response achieve completion 8 cycle treatment , patient continue study drug maintenance phase loss erythroid response ( return baseline hemoglobin transfusion requirement ) unacceptable toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Diagnosis DBA . 3.. Age &gt; =18 year time signing informed consent form . 4 . Able adhere study visit schedule protocol requirement . 5 . Red blood cell transfusiondependent requirement least one unit RBCs per month 2 month prior study enrollment ( e.g . 2 units/8 week ) 6 . If applicable , ongoing therapy stable decrease dose prednisone &lt; = 60 mg/d corticosteroid equivalent , treatmentrelated improvement RBC transfusion requirement least 2 month prior study entry 7 . ECOG performance status &lt; = 2 study entry . 8 . Laboratory test result within range : Absolute neutrophil count &gt; = 1500/mm &gt; = Platelet count &gt; = 100,000/mm &gt; = Serum creatinine &lt; = 2.0 mg/dL Direct bilirubin &lt; = 1.5 mg/dL AST ( SGOT ) ALT ( SGPT ) &lt; = 2.5 x ULN Disease free prior malignancy &gt; = 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 9 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 10 14 day prior within 24 hour prescribe lenalidomide ( prescription must fill within 7 day ) must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . See Appendix A : Risks Fetal Exposure , Pregnancy Testing Guidelines Acceptable Birth Control Methods . 10 . Able take aspirin ( 81 &gt; =25 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) . 3 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Use experimental drug therapy ( exclude steroid ) specifically use DBA within 28 day baseline include metoclopramide , leucine , danazol , hormonal therapy . 5 . Clinically significant anemia due factor iron , B12 , folate deficiency , autoimmune hereditary hemolysis , gastrointestinal bleeding . 6 . Known hypersensitivity thalidomide . 7 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 8 . Any prior use lenalidomide . 9 . Concurrent use anticancer agent treatment . 10 . Known positive HIV infectious hepatitis , type A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>